G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence

Lodato, Francesca; Azzaroli, Francesco; Tamè, Maria Rosa; Di Girolamo, Maria; Buonfiglioli, Federica; Mazzella, Natalia; Cecinato, Paolo; Roda, Enrico; Mazzella, Giuseppe; Larrubia, Juan-Ramón; Razonable, Raymund R.
November 2009
World Journal of Gastroenterology;11/21/2009, Vol. 15 Issue 43, p5449
Academic Journal
AIM: To evaluate the efficacy of granulocyte colony stimulating factors (G-CSF) in liver transplanted patients with hepatitis C (HCV) recurrence and Pegylated-IFN α-2b induced neutropenia, and to evaluate the impact of G-CSF administration on virological response. METHODS: Sixty-eight patients undergoing antiviral treatment for post-liver transplantation (OLT) HCV recurrence were enrolled. All patients developing neutropenia received G-CSF. RESULTS: Twenty three (34%) received G-CSF. Mean neutrophil count at the onset of neutropenia was 700/mmc (range 400-750/mmc); after 1 mo of G-CSF it increased to 1210/mmc (range 300-5590/mmc) (P < 0.0001). Three patients did not respond to G-CSF. Treatment duration was similar in neutropenic and non-neutropenic patients. No differences in the rate of discontinuation, infections or virological response were observed between the two groups. G-CSF was protective for the onset of de novo autoimmune hepatitis (P < 0.003). CONCLUSION: G-CSF administration is effective in the case of Peg-IFN induced neutropenia increasing neutrophil count, prolonging treatment and leading to sustained virological response (SVR) rates comparable to non-neutropenic patients. It prevents the occurrence of de novo autoimmune hepatitis.


Related Articles

  • Effectiveness of Antiviral Therapy for Post Transplantation Recurrence of Hepatitis C Virus Genotype 4: A Retrospective Study. Abdelrahim, Ayman Y.; Esmat, Gamal E.; Doss, Wheed H.; Abdelaziz, Ashraf O.; Abdelbary, Mohammad S.; Abdelaziz, Mohamed S.; Fathallah, Walid F.; Kady, Mohamed El // World Journal of Medical Sciences;2013, Vol. 8 Issue 3, p238 

    Recurrent hepatitis C after liver transplantation is universal. Treating HCV recurrence after successful liver transplantation has a number of major challenges. This study was carried out to assess the effectiveness of antiviral therapy for post transplantation recurrence of HCV genotype 4...

  • Intravenous Interferon Administered During Liver Transplantation Is Not Effective in Preventing Hepatitis C Reinfection. Russo, Mark; Narang, Tarun; Eskind, Lon; Hayes, Daniel; Casingal, Vincent; Purdum, Preston; Hanson, John; Ahrens, Will; Norton, James; Bonkovsky, Herbert // Digestive Diseases & Sciences;Oct2013, Vol. 58 Issue 10, p3010 

    Background: Post-transplant hepatitis C is a major challenge after liver transplantation (LT). Antiviral therapy is associated with lower efficacy in the post-transplant setting. Aims: The purpose of this study was to determine the safety and effect of intravenous interferon (IFN) during the...

  • Current Antiviral Therapy for Chronic Hepatitis C Including Liver Transplantation and Hepatic Resection. Hanazaki, Kazuhiro // Current Medicinal Chemistry - Anti-Infective Agents;Jun2003, Vol. 2 Issue 2, p103 

    Hepatitis C is an important cause of chronic liver disease, with an estimated 150 million persons worldwide. In the United States alone, about 2.7 to 4 million persons are infected with hepatitis C virus (HCV). Studies of the natural history have been somewhat contradictory but indicate that...

  • Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. Issa, D.; Eghtesad, B.; Zein, N. N.; Yerian, L.; Cruise, M.; Alkhouri, N.; Adams, R.; Hanouneh, I. A. // International Journal of Organ Transplantation Medicine;2016, Vol. 7 Issue 1, p38 

    Fibrosing cholestatic hepatitis (FCH) is an aggressive form of hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT), which frequently results in graft failure and death. Treatment of FCH remains challenging, and the optimal antiviral therapy is yet to be determined....

  • Recurrent Hepatitis C After Liver Transplantation. Khara, Harshit; Mukherjee, Sandeep // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Jun2010, Vol. 10 Issue 2, p91 

    No abstract available.

  • Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. Crespo, Gonzalo; Carrión, José; Coto-Llerena, Mairene; Mariño, Zoe; Lens, Sabela; Pérez-del-Pulgar, Sofía; García-Retortillo, Montserrat; Miquel, Rosa; Bosch, Jaime; Navasa, Miquel; Forns, Xavier // Journal of Gastroenterology;Jun2013, Vol. 48 Issue 6, p762 

    Background: The efficacy of antiviral therapy in patients with hepatitis C recurrence after liver transplantation (LT) is far from optimal and a careful selection of candidates with the best chances to achieve sustained virological response (SVR) is relevant. Moreover, investigating the effects...

  • Antiviral therap y for recurrent hepatitis C after liver transplantation and its effect on liver fibrosis. ZHOU Shuangan; ZHANG Min // Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;2014, Vol. 30 Issue 1, p27 

    Objective To perform antiviral therapy in patients with recurrent hepatitis C after liver transplantation ad to study the efficacy of anti-viral therapy ad its effect on the progression of liver fibrosis. Methods Twenty - three patients with recurrent hepatitis ? after liver transplanta-tion who...

  • Living-Donor Liver Transplantation and Hepatitis C. Nobuhisa Akamatsu; Yasuhiko Sugawara // HPB Surgery;2013, p1 

    Hepatitis-C-virus- (HCV-) related end-stage cirrhosis is the primary indication for liver transplantation in many countries. Unfortunately, however, HCV is not eliminated by transplantation and graft reinfection is universal, resulting in fibrosis, cirrhosis, and finally graft decompression. In...

  • On multi-strain model for Hepatitis C.  // Nonlinear Biomedical Physics;2011, Vol. 5 Issue 1, p6 

    The article offers information on the multi-strain model for hepatitis C virus (HCV), which also represents the basic properties of the immune system. It states that chronic HVC infection leads to liver transplant or death, while antiviral therapy is used to treat patients with HVC. It mentions...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics